Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia ; volume:7 ; number:1 ; day:4 ; month:10 ; year:2024 ; pages:1-11 ; date:12.2024
Communications biology ; 7, Heft 1 (4.10.2024), 1-11, 12.2024
- Urheber
-
Verbeek, Tamara C. A. I.
Vrenken, Kirsten S.
Arentsen-Peters, Susan T. C. J. M.
Castro, Patricia Garrido
Ven, Marieke van de
Tellingen, Olaf van
Pieters, Rob
Stam, Ronald W.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s42003-024-06916-w
- URN
-
urn:nbn:de:101:1-2412202100371.419670327820
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Verbeek, Tamara C. A. I.
- Vrenken, Kirsten S.
- Arentsen-Peters, Susan T. C. J. M.
- Castro, Patricia Garrido
- Ven, Marieke van de
- Tellingen, Olaf van
- Pieters, Rob
- Stam, Ronald W.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
Acute lymphoblastic leukemia
Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
RNA binding proteins in MLL-rearranged leukemia
Relapsed Acute Lymphoblastic Leukemia
High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Cardiac manifestation of acute lymphoblastic leukemia
Precision medicine in acute lymphoblastic leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
Acute lymphoblastic leukemia
Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
RNA binding proteins in MLL-rearranged leukemia
Relapsed Acute Lymphoblastic Leukemia
High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Cardiac manifestation of acute lymphoblastic leukemia
Precision medicine in acute lymphoblastic leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
Acute lymphoblastic leukemia
Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
RNA binding proteins in MLL-rearranged leukemia
Relapsed Acute Lymphoblastic Leukemia
High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Cardiac manifestation of acute lymphoblastic leukemia